Drugs / Heparan Sulphate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07684833 Comparator | Nov 2026 → May 2027 expected | chronic venous insufficiency | Farmaceutici Damor Spa | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Heparan Sulphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07684833 ↗ |
| Known as | CLR-07-23 | “CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets)” NCT07684833 ↗ |
| Known as | Heparan Sulfate | “CLR-07-23 (Heparan Sulfate 120 mg Prolonged-release Tablets)” NCT07684833 ↗ |
| Route | Oral | “administered orally” NCT07684833 ↗ |